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A green light for troponin T in the 
cardiovascular risk stratification of 
continuous ambulatory peritoneal 
dialysis patients?
C Zoccali1 and F Mallamaci1
Troponin T is specifically qualified as a predictor of circulatory overload 
in peritoneal dialysis (PD) patients. Given the good standardization and 
the high reproducibility of the troponin T assay, this measurement may 
prove useful in the clinical management of PD patients. It still remains to 
be tested whether clinical policies incorporating troponin T may actually 
produce better outcomes in PD patients.
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Prognosis and disease monitoring are 
essential elements of the decision cycle 
(that is, diagnosis, prognosis, treatment) 
that underpins clinical medicine. We base 
prognosis on well-established associations 
between clinical indicators (be they simple 
symptoms or signs of the disease in ques-
tion or results of imaging or biochemical 
studies) and the outcome of the disease. 
Furthermore, in everyday clinical practice 
we accurately monitor key indicators of 
disease activity to see whether therapeu-
tic interventions produce the expected 
favorable eff ects on the course of illness. 
Symptoms, physical signs, and clinical tests 
considered in the formulation of a progno-
sis or in the monitoring of the evolution of 
a disease should not necessarily refl ect a 
causal process implicated in the pathogen-
esis of the disease. In other words, the term 
‘prognostic factor’ denotes a variable that 
is statistically associated with a given out-
come independently of the nature (causal 
or non-causal) of the link between the 
variable and the outcome. Prognostic fac-
tors may be just disease indicators. Blood 
urea nitrogen per se does not determine 
organ damage, but it is a strong indicator 
of the severity of uremia — that is, a sur-
rogate of the combined eff ect of known 
and unknown uremic toxins. Th erefore 
we use blood urea nitrogen and indica-
tors derived from it (for example, Kt/V) to 
predict adverse outcomes and to quantify 
and monitor the eff ectiveness of removal 
of uremic toxins by dialysis in patients 
with end-stage renal disease (ESRD).
Cardiovascular prognosis: Echocardio-
graphy and cardiac biomarkers
Prognostic factors in general and biomark-
ers in particular must be sensitive, specifi c, 
and convenient, that is, inexpensive and 
easily measurable.1 Prognostic factors in 
general and biomarkers in particular must 
be sensitive, specifi c, and convenient, that 
is, inexpensive and easily measurable. 
Importantly, biomarkers should predict 
the outcome independently of other fac-
tors; that is, they should increase our ability 
to predict the outcome above and beyond 
established prognostic factors. Using a 
new prognostic factor or a new biomarker 
that is costlier and that does not allow a 
sensible gain in prediction power in com-
parison with a simpler and cheaper one is 
intrinsically senseless in clinical practice. 
Because the link between risk factors and 
clinical outcomes may vary in diff erent 
populations and disease states, validation 
of prognostic factors demands that they be 
specifi cally tested in the particular popu-
lation in which they are to be applied in 
clinical practice. Because the risk profi le 
in peritoneal dialysis (PD) patients diff ers 
from that in hemodialysis patients, prog-
nostic factors need to be validated sepa-
rately in these two populations.
Echocardiography is a fundamental 
technique for predicting the risk of death 
and cardiovascular complications in ESRD. 
Th is is because the presence and the sever-
ity of left  ventricular (LV) hypertrophy and 
LV dysfunction have been solidly associ-
ated with proportionate increases in the 
risk of death and cardiovascular events in 
well-conducted prospective studies2 and 
because it has been demonstrated that 
progression of LV hypertrophy3 and/or LV 
systolic dysfunction signals an increase in 
the risk of adverse events and vice versa. 
For this reason the measurement of LV 
mass and function is now legitimately 
considered in current guidelines as fun-
damental information for risk stratifi ca-
tion, and for disease monitoring as well. 
However, echocardiography is a time-con-
suming technique with a relevant cost. It 
is a common experience worldwide that 
time and cost constraints lead to underuse 
of the technique, thus denying important 
information to the clinical nephrologist. 
In the quest for cheaper and easily avail-
able disease indicators that may substitute 
for information traditionally obtained by 
echocardiography, much research eff ort 
has recently been made to test biomark-
ers of cardiac mass, function, and distress 
in ESRD patients. Troponin T appears 
to be of particular interest, and observa-
tions by Wang et al.4 (this issue) enlarge 
and extend to PD patients’ observations 
made in hemodialysis patients. Interest-
ingly, in the study by Wang et al.4 this 
marker was specifi cally qualifi ed as a pre-
dictor of circulatory overload, which is a 
frequent complication of much concern 
in PD patients. Although this outcome 
poses relevant problems of defi nition and 
detection, the authors took a pragmatic 
approach: they defined cardiovascular 
congestion on the basis of the need for 
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hospitalization and of another important 
criterion, the resolution of dyspnea and 
other symptoms aft er appropriate inten-
sifi cation of ultrafi ltration by hypertonic 
peritoneal fl uid exchanges.
Cardiac biomarkers: Natriuretic peptides 
and troponin T
Cardiac natriuretic hormones have been 
intensively studied in ESRD and in chronic 
kidney disease, and it is well known that 
the plasma concentration of these sub-
stances depends to an important extent 
on their reduced renal clearance. How-
ever, in hemodialysis patients, alterations 
in LV mass and function appear to be a 
much more relevant factor than abolished 
renal clearance for the high plasma lev-
els of these peptides. Indeed, both atrial 
and brain natriuretic peptides are only 
slightly increased in ESRD patients with 
normal LV mass but attain high levels 
in those with severe LV hypertrophy.5 
Because cardiac natriuretic hormones, 
brain natriuretic peptide in particular, 
refl ect cardiac preload and aft erload, they 
provide an index of cardiac stress and are 
highly predictive of death and cardiovas-
cular outcome in ESRD patients.5 In the 
general population, plasma brain natriu-
retic peptide is a cost-eff ective method of 
screening for LV dysfunction, particularly 
in individuals at high cardiovascular risk, 
and the measurement of this peptide is of 
well-proven usefulness to guide treatment 
in patients with heart failure.6
Troponin T is an established biomarker 
extensively applied for the diagnosis and 
the prognosis of coronary heart disease in 
the acute setting. In recent years impor-
tant new knowledge has been gained on 
the biology and the long-term prognostic 
value of this biomarker in various con-
ditions, including ESRD. In apparently 
asymptomatic, stable dialysis patients, 
multivessel coronary artery disease diag-
nosed by angiography is more prevalent 
with progressively greater quartiles of 
troponin T,7 and it is a strong predictor 
of death and cardiovascular events. Like 
brain and atrial natriuretic peptides, tro-
ponin T accumulates in uremic patients 
because of reduced or abolished renal 
clearance,8 but here again, this biomar-
ker has shown remarkable relationships 
with LV mass and function. Indeed, in 
asympto matic hemodialysis patients tro-
ponin T rises in parallel with LV mass and 
mirrors declining LV systolic function.9 
Th ese relationships probably refl ect sub-
tle myocardial-cell ischemia brought about 
by perfusion mismatch, that is, inadequate 
development of the capillary network in 
the hypertrophic left  ventricle of ESRD 
patients, an alteration aggravated by the 
propensity of the uremic myocardium to 
undergo interstitial fi brosis. In this situ-
ation, myocardial-cell hypoxia facilitates 
leakage of myocardial-cell proteins such as 
troponin T into the systemic circulation 
(Figure 1). Notably, it has been repeatedly 
confi rmed that troponin T is a powerful 
death predictor, and a recent metaanaly-
sis has nicely shown that high troponin T 
(>0.1 ng ml–1) conveys a 2.6 times higher 
risk of death in asymptomatic dialysis 
patients.10 A substantial advantage of 
troponin T over other cardiovascular risk 
biomarkers that has not been suffi  ciently 
emphasized is that the assay of this pro-
tein is produced by a single manufacturer, 
which may guarantee the required stand-
ardization of the assay results.
Why is troponin T, a myocardial-cell 
protein, a predictor of cardiovascular 
outcomes independently of LV mass?
An interesting finding of the study by 
Wang et al.4 is that troponin T predicts 
cardiovascular congestion independ-
ently of LV mass, the strongest predictor 
of adverse cardiovascular outcomes in 
ESRD. Because of the intimate and con-
sistent link between troponin T and altera-
tions in myocardial mass, one would have 
indeed expected a substantial loss in the 
prognostic value of this cardiac protein 
in statistical models including LV mass, 
which was not the case. Th is phenomenon 
most likely depends on methodological 
and biological factors, methodological 
ones probably being the most relevant. 
Troponin T can be measured with high 
precision. Indeed both the interassay and 
the intra-assay coeffi  cient of variation is 
as low as 3%. In contrast, measurement of 
LV mass by echocardiography has a high 


















Normal or mild to
moderate LVH




Figure 1 | CHD, LVH and troponin T in ESRD. Coronary heart disease (CHD) and left ventricular 
hypertrophy (LVH) are frequent in end-stage renal disease patients and contribute to rising plasma 
troponin T levels. The plasma concentration of this protein may be seen as a composite indicator 
of these stressful influences on the myocardial cell (left panel). Patients with high troponin T 
may be more sensitive to the detrimental effects of volume overload; that is, they may have a 
lower threshold for symptoms of circulatory overload. Clinical symptoms and signs of circulatory 
congestion are expected to appear with small or moderate degrees of volume expansion in 
patients with high troponin T, whereas more marked increases in volume expansion may be 
required to determine the same outcome in patients with normal or mildly increased troponin T 
(right panel). LV, left ventricular hypertrophy.
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variation (90% confi dence interval, –18% 
to +18%), and the interobserver coeffi  cient 
of variation is also fairly high.11 Th us the 
prediction power of troponin T, which in 
a way is a biochemical marker of LV mass, 
may refl ect residual confounding attribut-
able to the fact that LV mass is measured 
imprecisely by echocardiography. In other 
words, adjustment for LV mass might not 
take away the whole eff ect of this factor. 
On the other hand, in biological terms, 
troponin provides information that goes 
beyond LV mass and function, because 
the plasma concentration of this substance 
refl ects myocardial-cell distress. Th us it 
may also be that the good prediction power 
of troponin T depends on the fact that this 
biomarker adds relevant biological infor-
mation (myocardial-cell distress) to that 
provided by echocardiographic measure-
ment of LV mass. As is mentioned above, 
the fact remains that this biomarker, inde-
pendently of the nature of the link between 
plasma troponin and circulatory overload, 
emerges as a most promising prognostic 
factor for this outcome in PD patients. 
Validation of a biomarker is a complex 
process1 that also requires appropriate 
studies testing whether measurement of 
the biomarker is useful in clinical prac-
tice. The United States Food and Drug 
Administration approved the measure-
ment of troponin T in dialysis patients for 
risk stratifi cation. However, a prospective, 
randomized clinical trial testing the value 
of troponin in a clinical decision-making 
context is still needed to solidly estab-
lish the place of this biomarker in eve-
ryday clinical practice in ESRD patients. 
For example, should these patients be 
intensively treated by a pharmacological 
approach, or should they be considered 
for coronary revascularization even in the 
absence of symptoms? Th e study by Wang 
et al.4 off ers an important new piece of 
evidence on the potential usefulness of 
troponin T in asymptomatic PD patients 
and makes even more compelling the case 
for prospectively testing treatment policies 
that incorporate this biomarker in the 
management of these patients.
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Myostatin and insulin-like growth 
factors in uremic sarcopenia: 
the yin and yang in muscle mass 
regulation
RH Mak1 and P Rotwein2
Myostatin and the insulin-like growth factors (IGF-I and -II) play inhibitory 
and stimulatory roles, respectively, in the development and regulation of 
skeletal muscle mass. The findings of Sun et al. in this issue shed light on 
the potential regulation and actions of this yin-and-yang system in uremic 
sarcopenia and the salutary effects of exercise.
Kidney International (2006) 70, 410–412. doi:10.1038/sj.ki.5001622
Myostatin (also known as growth/diff eren-
tiation factor-8) is a member of the trans-
forming growth factor-β family that plays 
an essential role in the regulation of skel-
etal muscle mass. Myostatin is expressed 
initially in the myotomal compartment of 
developing somites and continues to be 
expressed in muscle throughout develop-
ment and in adult animals. Mice with a 
targeted disruption of the myostatin gene 
display a marked increase in muscle mass, 
up to three times normal size, as a result of 
a combination of muscle fi ber hyperplasia 
and hypertrophy. Th e myostatin sequence 
has been highly conserved throughout evo-
lution. Remarkably, the human, rat, mouse, 
porcine, turkey, and chicken proteins are 
identical in the biologically active COOH-
terminal portion of the molecule. Th e func-
tion of myostatin as an inhibitor of skeletal 
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